Iovance Biotherapeutics's total assets for Q3 2024 were $991.12M, an increase of 2.78% from the previous quarter. IOVA total liabilities were $217.66M for the fiscal quarter, a 11.17% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.